PYXS Pyxis Oncology Inc

$PYXS That MASSIVE offering dilution below $3 rarely bodes well for biotechs long term. And the gazillion warrant overhang up there at 3.50. Talk about a great way to mute any potential significant gains. Looking at this IMO, at current price of 1.67, I estimate the upside potential of 80% at 15% (near term), vs. downside potential of 40% at 50% probability. Sure there will be 10-15% bounces but I think this, along with most other biotechs are headed down significantly. Good luck

$PYXS hope she hasn't taken the direction of so many other biotechs or a lot of sad red days are waiting for us.

$PYXS some other CEO stated that we are in a difficult financing environment for biotechs. $PYXS got lots of cash with very favorable terms. If this is not a positive...

$PYXS whole sector needs more recognition .. money might flow out of AI backk in to these

$PYXS around $ 3 - 4 without news for months; drop under $ 2 and more with the news of the successful completion of its public offering. Manipulation nation, world domination.

$PYXS Another reason I bought this Friday. It sold off dead to support. I actually thought it would bounce more than this today but at least it’s a start.

$PYXS On October 02, 2026, Pyxis Oncology Inc (NASDAQ: PYXS) announced the successful completion of its previously announced public offering, raising approximately $110 million in gross proceeds before fees.

$PYXS Overall assessment - Pyxis has a credible early clinical signal and a substantially improved cash position. Those are real positives. But the financing was highly dilutive, the Phase 3 program is not fully covered by current funds unless warrants are exercised or more capital is raised, and the clinical evidence remains too early to call MICVO a proven asset. I’d classify PYXS as a high-risk, catalyst-driven biotech investment, not a straightforward low-priced value stock. The $2.02 quote is less important than the roughly $240–245 million basic equity value, the potential 69 million additional shares from the two major warrant blocks, and whether the Phase 1 signal survives a randomized Phase 3 test. A bullish investor can make a case for meaningful upside if MICVO works; a cautious investor can reasonably wait for combination data, further survival follow-up, or clearer Phase 3 funding before deciding whether that risk is worth taking.

$PYXS Imaginingbthat those who spent 100s of mio of $ would not be capable to bring the shareprice where they want it to be is ludicrous. Strongedt buy.